New oral drug shows promise for Long-Term control of rare bleeding disorder
NCT ID NCT07216079
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited from the drug in a prior study will continue treatment. The goal is to see if the drug remains safe and effective over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rilzabrutinib (oral tablet)
What this could lead to
If successful, this study could show that rilzabrutinib is a safe and effective long-term treatment option for managing chronic immune thrombocytopenia.
What could go wrong
This is a very small extension study (only 4 participants) with no placebo group, so results may not apply broadly. Long-term safety and effectiveness are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number: 1001
Tsuchiura, Ibaraki, 300-0028, Japan
-
Investigational Site Number: 1002
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Investigational Site Number: 1003
Iruma-gun, Saitama, 350-0495, Japan